Efficacy and Safety of Co-administered Cagrilintide and Semaglutide (CagriSema 2.4 mg/2.4 mg) Once Weekly Versus Semaglutide 2.4 mg, Cagrilintide 2.4 mg and Placebo in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity
Efficacy and Safety of Co-administered Cagrilintide and Semaglutide (CagriSema 2.4 mg/2.4 mg) Once Weekly Versus Semaglutide 2.4 mg, Cagrilintide 2.4 mg and Placebo in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity
This study will look if CagriSema can lower kidney damage in people with chronic kidney disease (CKD), type 2 diabetes (T2D) and overweight or obesity. CagriSema is a new investigational medicine. CagriSema cannot yet be prescribed by doctors. The study will compare CagriSema to the 2 medicines semaglutide and cagrilintide, when they are taken alone. It will also compare CagriSema to a "dummy" medicine (also called placebo) without any active ingredient. Participant will either get CagriSema, semaglutide, cagrilintide or placebo. Which treatment participant will get is decided by chance (like flipping a coin). Study doctor will not know which of the study medicines participant will get. For each participant, the study will last for about 35 weeks.
Inclusion Criteria:
Exclusion Criteria:
CABA, Buenos Aires C1128 AAF, Argentina
Porto Alegre, Rio Grande do Sul 90430-001, Brazil
Rio, Patra, 26504, Greece
Hyderabad, Andhra Pradesh 500082, India
Pune- Maharashtra, Maharashtra 411011, India
Koriyama-shi, Fukushima, Fukushima, Japan 963-8851, Japan
Hokkaido, 062-0007, Japan
Mito-shi, Ibaraki, 311-4153, Japan
Bialystok, Podlaskie Voivodeship 15-435, Poland
Klong Luang, Changwat Pathum Thani 12120, Thailand